3 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • DIAGNOSTIC TEST - LUNG CANCER
  • DIAGNOSTIC TEST - BREAST CANCER

Summary Armune BioScience Inc (Armune) is a medical device company that develops and commercializes molecular diagnostic and prognostic tests. The company uses genomics and proteomics in cancer to identifying specific sets of genes or proteins. It develops protein signature based diagnostic tests for prostate, lung...

  • Cancer
  • United States
  • Company
  • Product Initiative
  • Armune BioScience, Inc.
  • 02/23/2016: AETERNA ZENTARIS COMMENCES PROMOTIONAL ACTIVITIES FOR APIFINY PROSTATE CANCER BLOOD TEST
  • EXACT SCIENCES ACQUIRES ARMUNE BIOSCIENCE

Summary Armune BioScience Inc (Armune BioScience), a subsidiary of Exact Sciences Corp is a medical device development company that develops and commercializes molecular prognostic and diagnostic tests.The company uses genomics and proteomics in cancer to identifying specific sets of genes or proteins. It develops...

  • Cancer
  • Medical Device
  • United States
  • Company
  • Armune BioScience, Inc.